TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06757556

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-starchy vegetables will be provided to the participants as an intervention.
Description: Intervention will consist of provision of vegetables (based on WHO criteria of 2-3 servings) to overweight and obese adults fo weight loss purpose.
Study: NCT05433038

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: skeletally anchored maxillary expander
Description: used from day one and activated two times per day for two weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: skeletally anchored maxillary expander
Description: used from day one and activated two times per day for two weeks
Study: NCT05131776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-guided oncosil injection
Description: All patients will receive OncoSilTM during the 4th week of the first chemotherapy cycle.
Study: NCT03591614

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DKK1
Description: The investigational agent is a DKK1 peptide-loaded autologous dendritic cell vaccine dispensed at a dose of 5-10x106 in 0.5 mL Plasma-Lyte A + 5% HSA.
Study: NCT05884112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAGSTIM reprtitive Transcranial Magnetic Stimulator (rTMS) System
Description: iTBS is a new treatment method for depression. It uses the principle of magnetoelectricity to intermittently stimulate local brain nerves. In recent years, domestic and foreign studies have confirmed its efficacy and safety for depression. In addition, research has also It shows that iTBS has better therapeutic effect and efficiency than the previous regular rTMS.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham control
Description: sham control
Study: NCT05985876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KULEA-NET application
Description: African American/Black (AA/B) women recruited at 3 distinct stages of pregnancy - i.e. 1) 29 to 34 weeks gestational age, 2) 35 to 40 weeks gestational age, and 3)immediately post-partum, will be assigned to the intervention group and start using the KULEA-NET platform. Women in the intervention arm #1 will use KULEA-NET for a total duration of approximately 9 months (3 months prenatal and 6 months post-partum; women in the intervention arm #2 will use KULEA-NET for a total duration of approximately 7 months (1 month prenatal and 6 months post-partum); and women in the intervention arm #3 will use KULEA-NET for a total duration of approximately 6 months (only post-partum). Each woman will have access to all components of the KULEA-NET platform: the text messages, knowledge base, 3 different types of videos, and breastfeeding-friendly spaces and breastfeeding classes near them.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Group: Usual Care
Description: Control participants will receive usual care i.e. standard obstetrical care at MWHC and Mamatoto Village and will receive standard Babyscripts app only without the KULEA-NET tile. Information from the ACOG about the maternal and infant health benefits of breastfeeding will also be provided (e.g., they will get pamphlets on the importance of breastfeeding as well as lactation consultation).
Study: NCT05517928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 40 MG oral capsules daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omeprazole
Description: 40 MG oral capsules daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Description: Given as Culturelle Digestive Probiotic in the form of oral capsules daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules daily that look exactly like the study drug, but contains to active ingredient
Study: NCT04679896

Intervention type: DEVICE
Group type: OTHER
Intervention: MagnetOs Putty
Description: Procedure: Instrumented posterolateral spine fusion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagnetOs Putty
Description: Procedure: Instrumented posterolateral spine fusion
Study: NCT04941001

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReferID
Description: The ReferID tool is a digital tool which can be used to facilitate a review of asthma in primary care
Study: NCT05576493

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phaco+MP-TSCPC
Description: The procedure starts with performing the cyclophotocoagulation using the Micropulse P3 device (IQ 810 Laser Systems; Iridex, Mountain View, CA, USA) at 2500 mW with a duration of 90 seconds in each hemisphere at a 31.3% duty cycle under local anesthesia and then performing phacoemulsification and IOL implantation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phaco+TSCPC
Description: The procedure starts with performing the cyclophotocoagulation using the IRIDEX's G probe device (IRIDEX Corp. Mountain View, CA, USA) at 1500 to2000 mW with a duration of 1500 ms applying about 15 shots in one hemisphere only under local anesthesia and then performing phacoemulsification and IOL implantation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phaco+endocyclophotocoagulation
Description: phacoemulsification will be done and endocyclophotocoagulation will be done after cataract extraction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phaco GSL
Description: phacoemulsification will be done and then the angle is visualized by direct goniolens then the synechia are dissected by cohesive viscoelastic.
Study: NCT05453344

Intervention type: DEVICE
Group type: OTHER
Intervention: DexCom one
Description: Provision of DexCom One for glucose monitoring
Study: NCT05657678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 - 750 000 IU
Description: a single administration of 750,000 IU of vitamin D3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 - 500 000 IU
Description: a single administration of 500,000 IU of vitamin D3
Study: NCT05837806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab+disitamab-vedotin
Description: patients in group will receive 3 cycles of tislelizumab 200 mg in combination with disitamab-vedotin 120 mg intravenously.
Study: NCT06509204

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucotrojan
Description: Day 1: Start wearing the CGM sensor and let it self-calibrate for 24 h Day 2: Consume 1 serving of Test Meal for breakfast. Log the meal in the app. Day 3: Consume 1 serving of Test Meal with GlucoTrojan for breakfast. Log the meal in the app.~Days 4-8: Participants will be instructed to take GlucoTrojan twice per day. Once during their typical breakfast meal and once during their typical dinner meal. Each breakfast and dinner will be logged in the app.~Days 9-13: Participants will continue with their typical lives but continue to log meals - breakfast and dinner - in the app.~Day 14: end
Study: NCT05701579

Intervention type: PROCEDURE
Intervention: ACL decompression
Description: The technique of ACL decompression by the means of longitudinal incisions and evacuation of extrafibrous mucoid tissue.
Study: NCT05697536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates training
Description: It consists of patients who will receive pilates exercise training sessions 3 times per week for 8 weeks. Every session will be of 45 minutes. Exercise programs follow the basic principles of pilates method but particularly movements with low and medium difficulty levels will be chosen to adapt the program to the physical capacity of the patients.~Protocol will be compromise of 9 modules: postural education, search for neutral position, sitting exercise, antalgic exercise, stretching exercises, proprioceptively improvement exercises and breathing exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: It consists of patients who will receive aerobic exercise sessions 3 times per week for 8 weeks. Every session will be of 45 minutes.~It will include warm up phase, active phase and
Study: NCT06019247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual placement support (IPS)
Description: IPS is the most studied psychiatric rehabilitation intervention in the world. It is based on eight principles: inclusion of all clients who have declared a desire to work, no pre-vocational training, benefits counseling, rapid job search, treatment team-level integration of vocational and clinical services, consideration of client preferences in all decisions, assistance in job development, provision of follow-up supports after finding employment, and a focus on competitive employment. We propose to adapt and pilot the IPS to improve employment and health among people with severe mental disorders in Mexico.
Study: NCT05616494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel for injection (Albumin-bound)
Description: Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks.
Study: NCT04648215

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lavender oil
Description: aromatherapy--two drops applied to a 2x2 gauze and pinned to subject's gown

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Grapeseed Oil
Description: aromatherapy--two drops applied to a 2 X 2 gauze and pinned to subject's gown
Study: NCT05243459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gaze-Contingent Feedback Training
Description: Feedback according to participants' viewing patterns, in order to modify their attention away from threat face stimuli.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Bias Modification
Description: Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli using threat and neutral face stimuli.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-Contingent Feedback Training
Description: Participants listen to a musical track they chose while viewing the face matrices. The music is played throughout and is not contingent upon gaze behavior.
Study: NCT06338514

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Real dry needling
Description: dry needling into the muscle under ultrasound guidance.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham dry needling
Description: dry needling into the subcutaneous fatty tissue under ultrasound guidance.
Study: NCT05291975

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erchonia® EVRL™
Description: The Erchonia® EVRL™ is made up of (1) 635 nanometers red laser diode and (1) 405 nanometers violet laser diode mounted in a portable handheld device. The diodes are positioned approximately 3 to 6 inches from the top of the foot. The treatments will be self-administered by the subject at his or her's place of residence, two times per day for 21 days. Each procedure administration lasts 5 minutes per foot, for a total of 10 minutes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Laser
Description: The Placebo Laser has the same appearance as the Erchonia® EVRL™ but does not emit any therapeutic light. The diodes are positioned approximately 3 to 6 inches from the top of the foot. The treatments will be self-administered by the subject at his or her's place of residence, two times per day for 21 days. Each procedure administration lasts 5 minutes per foot, for a total of 10 minutes.
Study: NCT05763615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tractography MRI
Description: Addition to the sequences usually done for the care of these patients (CubeT2, Diffusion, CubeT1, CubeT2 fiesta, ASL, T1 injected with gadolinium), of a so-called research tractography sequence benefiting from CE marking and not requiring specific injection.~Search sequence acquisition time: 10 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tractography MRI
Description: Addition to the sequences usually done for the care of these patients (CubeT2, Diffusion, CubeT1, CubeT2 fiesta, ASL, T1 injected with gadolinium), of a so-called research tractography sequence benefiting from CE marking and not requiring specific injection.~Search sequence acquisition time: 10 minutes.
Study: NCT04972227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CY6463
Description: oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablets
Study: NCT05980650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki implication
Description: Reiki will be implicate by researcher by putting hands on patient
Study: NCT06127394

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sacral ESP Block
Description: Sacral ESPB median approach, 40 ml %0,25 Bupivacaine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pudendal Block
Description: Bilateral pudendal block, 10 ml %0,25 bupivacaine
Study: NCT05499091

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsy, blood sample, urine sample
Description: blood samples, urine samples, skin samples.
Study: NCT05679167

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised digital training with focus on core stability
Description: After randomization, Group 1 will be digitally supervised by experienced physiotherapist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised digital training with focus on core stability
Description: After randomization, Group 1 will be digitally supervised by experienced physiotherapist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised digital training with focus on aerobic exercise
Description: After randomization Group 2 will be digitally supervised by experienced physiotherapist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised digital training with focus on aerobic exercise
Description: After randomization Group 2 will be digitally supervised by experienced physiotherapist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-supervised daily physical activity
Description: After randomization Group 3 will receive training instruction regarding daily physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-supervised daily physical activity
Description: After randomization Group 3 will receive training instruction regarding daily physical activity.
Study: NCT04963530

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment with monolithic zirconia restorations
Description: Treatment with monolithic zirconia restorations on teeth (single crowns). The sample (75 patients) will be divided into three groups according to the ceramic material used: monolithic zirconia, lithium disilicate and metal ceramic.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment with lithium disilicate restorations
Description: Treatment with lithium disilicate restorations on teeth (single crowns). The sample (75 patients) will be divided into three groups according to the ceramic material used: monolithic zirconia, lithium disilicate and metal ceramic.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment with metal ceramic restorations
Description: Treatment with metal ceramic restorations on teeth (single crowns). The sample (75 patients) will be divided into three groups according to the ceramic material used: monolithic zirconia, lithium disilicate and metal ceramic.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No intervention
Description: No intervention.
Study: NCT05347927

Intervention type: DEVICE
Intervention: water resistante padding
Description: * Delta-Dry® Softliner~* Tensoban®~* Delta-Dry®

Intervention type: DEVICE
Intervention: non water resistante padding
Description: * Delta-Net® Stockinette~* Delta-Rol®
Study: NCT05150171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-self-management intervention
Description: The app is developed based on a combination of behavioural change techniques informed by Social cognitive theory and the EULAR recommendations on management of hand osteoarthritis. The 12-week intervention consists of 25 short informational videos addressing the themes prioritized by the patient research partners. Additionally, the intervention includes a hand exercise program consisting of 8 videos providing instructions on warm up, exercises to improve mobility, strength and coordination, and a stretching exercise. The informational videos and exercise program are delivered in a progressive order across the 12 weeks. Encouragement and motivational messages are provided each week to enhance continued adherence to the intervention.
Study: NCT05785325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC plus Bevacizumab
Description: Administer RC48-ADC intravenously in combination with bevacizumab 5mg/kg once every two weeks.
Study: NCT06227988

Intervention type: PROCEDURE
Intervention: patients with liver disease who undergoing surgery
Description: For each patient and surgery, we will be collecting detailed pre-operative data regarding demographics (age, sex, body mass index, surgery category, comorbidities (diabetes mellitus, hypertension), and pertinent laboratory values (sodium, creatinine, total bilirubin, the international normalized ratio \[INR\], albumin, platelet count.) The etiology of liver disease will be classified.~To ensure that laboratory data accurately reflected the pre-operative state, only those from within 30 days prior to surgery will be considered For each patient VOCAL PENN score, MELD score, and Mayo score will be calculated using an online calculator.

Intervention type: PROCEDURE
Intervention: patients with liver disease who undergoing surgery
Description: For each patient and surgery, we will be collecting detailed pre-operative data regarding demographics (age, sex, body mass index, surgery category, comorbidities (diabetes mellitus, hypertension), and pertinent laboratory values (sodium, creatinine, total bilirubin, the international normalized ratio \[INR\], albumin, platelet count.) The etiology of liver disease will be classified.~To ensure that laboratory data accurately reflected the pre-operative state, only those from within 30 days prior to surgery will be considered For each patient VOCAL PENN score, MELD score, and Mayo score will be calculated using an online calculator.

Intervention type: PROCEDURE
Intervention: patients with liver disease who do not undergoing surgery
Description: For each patient and surgery, we will be collecting detailed pre-operative data regarding demographics (age, sex, body mass index, surgery category, comorbidities (diabetes mellitus, hypertension), and pertinent laboratory values (sodium, creatinine, total bilirubin, the international normalized ratio \[INR\], albumin, platelet count.) The etiology of liver disease will be classified.~To ensure that laboratory data accurately reflected the pre-operative state, only those from within 30 days prior to surgery will be considered For each patient VOCAL PENN score, MELD score, and Mayo score will be calculated using an online calculator.

Intervention type: PROCEDURE
Intervention: patients with liver disease who do not undergoing surgery
Description: For each patient and surgery, we will be collecting detailed pre-operative data regarding demographics (age, sex, body mass index, surgery category, comorbidities (diabetes mellitus, hypertension), and pertinent laboratory values (sodium, creatinine, total bilirubin, the international normalized ratio \[INR\], albumin, platelet count.) The etiology of liver disease will be classified.~To ensure that laboratory data accurately reflected the pre-operative state, only those from within 30 days prior to surgery will be considered For each patient VOCAL PENN score, MELD score, and Mayo score will be calculated using an online calculator.
Study: NCT04622163

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Secondary Mentor
Description: Subjects will be matched with a secondary mentor from the Department of Medicine for 6 months. Mentors and mentees are expected to hold one-on-one meetings monthly for the first 3 months followed by at least once every 3 months thereafter.

Intervention type: OTHER
Group type: OTHER
Intervention: Career Development Resources
Description: Subjects will receive career development resources.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Career Development Resources
Description: Subjects will receive career development resources.
Study: NCT05707494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Efferon LPS NEO
Description: Efferon LPS NEO, a medical device, which is a cylindrical body filled with a polymeric hemosorbent that selectively absorbs LPS and excess cytokines. The device is used for extracorporeal therapy to relieve septic shock in the treatment of sepsis.
Study: NCT05499767

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEPPI
Description: Homebound Elderly People Psychotherapeutic Intervention
Study: NCT05785637

Intervention type: PROCEDURE
Intervention: Polygraphy diagnostic at home
Description: Polygraphy diagnostic at home for patients under non-invasive mechanical ventilation.
Study: NCT04931290

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supracapsular Ahmed Glaucoma Valve plate delivery technique
Description: incision of the perilimbal superior temporal conjunctiva with separation of the conjunctiva from the Tenon's capsule till reaching the encapsulated valve plate. Incision of the capsule in a z pattern will be done then the plate is dissected from the tissues and delivered out of the capsule through the opening to the subconjunctival space.The mobility of AGV and its tube will be evaluated and refixation of the plate will be done if needed. The plate will be covered with ologen implant sizing 12mm width and 1 mm thickness. The conjunctiva will be closed by 10/0 nylon sutures.